Regeneron Pharmaceuticals Inc. (REGN) announced Monday morning that results from two Phase 2 studies that added the angiopoietin2 antibody nesvacumab to EYLEA Injection did not provide sufficient differentiation to warrant Phase 3 development.
from RTT - Before the Bell http://ift.tt/2BjaLVa
via IFTTT
No comments:
Post a Comment